1.94
price down icon8.49%   -0.18
pre-market  Vorhandelsmarkt:  1.93   -0.01   -0.52%
loading
Schlusskurs vom Vortag:
$2.12
Offen:
$2.11
24-Stunden-Volumen:
876.87K
Relative Volume:
0.56
Marktkapitalisierung:
$246.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.44M
KGV:
-5.5429
EPS:
-0.35
Netto-Cashflow:
$-42.28M
1W Leistung:
+10.86%
1M Leistung:
-10.39%
6M Leistung:
+12.79%
1J Leistung:
+31.08%
1-Tages-Spanne:
Value
$1.91
$2.15
1-Wochen-Bereich:
Value
$1.68
$2.19
52-Wochen-Spanne:
Value
$0.765
$4.08

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name
Firmenname
Compass Therapeutics Inc
Name
Telefon
617-500-8099
Name
Adresse
80 GUEST STREET, BOSTON
Name
Mitarbeiter
35
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CMPX's Discussions on Twitter

Vergleichen Sie CMPX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CMPX
Compass Therapeutics Inc
1.94 246.14M 0 -45.44M -42.28M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-02 Hochstufung Leerink Partners Market Perform → Outperform
2025-02-24 Eingeleitet Guggenheim Buy
2025-02-19 Eingeleitet Piper Sandler Overweight
2024-12-23 Eingeleitet D. Boral Capital Buy
2024-11-15 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-16 Hochstufung Ladenburg Thalmann Neutral → Buy
2023-01-31 Eingeleitet Jefferies Buy
2023-01-27 Eingeleitet Stifel Buy
2022-05-23 Fortgesetzt H.C. Wainwright Buy
2022-03-15 Eingeleitet Ladenburg Thalmann Buy
2022-01-19 Eingeleitet B. Riley Securities Buy
2021-12-22 Eingeleitet Raymond James Outperform
2021-12-20 Eingeleitet SVB Leerink Outperform
2021-12-15 Eingeleitet Wedbush Outperform
Alle ansehen

Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten

pulisher
04:45 AM

Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC - Defense World

04:45 AM
pulisher
Apr 27, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Apr 27, 2025
pulisher
Apr 24, 2025

It is Poised to be a Bull Market for Compass Therapeutics Inc (CMPX) - Sete News

Apr 24, 2025
pulisher
Apr 24, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from Guggenheim - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

What was Compass Therapeutics Inc (CMPX)’s performance in the last session? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Compass Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.2378: Will the Stock Break Through? - investchronicle.com

Apr 23, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from HC Wainwright - Defense World

Apr 22, 2025
pulisher
Apr 22, 2025

Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Inc [CMPX] Insider GORDON CARL L sells 3,571,428 Shares – Latest News - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug By Investing.com - Investing.com Canada

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics begins biliary cancer trial with new drug - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Doses First Patient in Investigator Sponsored Trial of Tovecimig for Biliary Tract Cancer - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Compass Therapeutics Announces First Patient Dosed in an - GlobeNewswire

Apr 21, 2025
pulisher
Apr 14, 2025

Compass Therapeutics Insider Sold Shares Worth $5,678,571, According to a Recent SEC Filing - marketscreener.com

Apr 14, 2025
pulisher
Apr 12, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares By Investing.com - Investing.com UK

Apr 12, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Compass Therapeutics director Carl Gordon sells $5.68 million in shares - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Orbimed advisors sells $5.68 million in Compass Therapeutics shares - Investing.com

Apr 11, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics chief accounting officer acquires $28,400 in stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics general counsel buys $30,800 in common stock - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Compass Therapeutics Executives Increase Holdings - TradingView

Apr 08, 2025
pulisher
Apr 06, 2025

Wedbush Research Analysts Lower Earnings Estimates for CMPX - The AM Reporter

Apr 06, 2025
pulisher
Apr 05, 2025

HC Wainwright Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World

Apr 05, 2025
pulisher
Apr 05, 2025

Leerink Partnrs Has Pessimistic Outlook of CMPX Q2 Earnings - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

FY2028 EPS Estimates for Compass Therapeutics Cut by Wedbush - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partnrs - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Leerink Partners Upgrades Compass Therapeutics (NASDAQ:CMPX) to Outperform - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint - insights.citeline.com

Apr 04, 2025
pulisher
Apr 03, 2025

Compass Therapeutics price target raised to $11 from $10 at Stifel - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from D. Boral Capital - The AM Reporter

Apr 03, 2025
pulisher
Apr 02, 2025

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics (CMPX) - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics rises on trial win for biliary tract cancer therapy - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink raises Compass Therapeutics stock rating, PT to $6 from $4 - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics And 2 More Compelling Penny Stocks - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Leerink Partners Upgrades Compass Therapeutics to Outperform From Market Perform, Adjusts PT to $6 From $4 - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics Target of Unusually Large Options Trading (NASDAQ:CMPX) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Compass Therapeutics (NASDAQ:CMPX) Given Outperform Rating at Wedbush - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Clinical Breakthrough Propels Compass Therapeutics (CMPX) Stock Higher - Stocks Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics: Exploring Surging Potential? - timothysykes.com

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Reports Positive Phase 2/3 Trial Results For Tovecimig - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed - Endpoints News

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics stock down amid trial win (CMPX:NASDAQ) - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate - MarketScreener

Apr 01, 2025

Finanzdaten der Compass Therapeutics Inc-Aktie (CMPX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):